| Home | E-Submission | Sitemap | Contact Us |  
Korean Journal of Clinical Oncology > Article
REVIEW
Korean J Clin Oncol. 2010;6(2): 70-77.         doi: https://doi.org/10.14216/kjco.10022
Evaluation of serum HER-2/neu in breast cancer patients: correlation with clinicopathological parameters and survival
Dong Won Ryu, Woo Sik Choi, Chung Han Lee
Surgery department of Kosin University Hospital in Pusan, Korea
유방암 환자의 혈청 HER-2/neu 농도의 임상적 중요성 및 생존율과의 관련성
류동원, 최우식, 이충한
고신대학교 외과
Corresponding Author: Chung Han Lee ,Tel: +82-51-990-6462, Fax: +82-51-243-6093, Email: lovebreast@naver.com
Received: November 20, 2010;  Accepted: December 23, 2010.
Share :  
ABSTRACT
Purpose: the extracellular ligand-domains of HER-2/neu can be detected in the bloodstream. Many reports have determined the association between increased serum HER-2/neu concentration and decreased response the chemotherapy. The aims of our study were to assess the correlation between serum HER-2/neu and clinocopathologic factors and to assess the effect of serum HER-2/neu on disease free survival rate. Materials and
Methods: The study subjects, 167 women with breast cancer, were a subset of patients operated at OOO hospital from Jan 2005 to Dec 2006. Patients are grouped into 2 categories according to serum HER-2/neu determined in the preoperative serum level. Clincopathologic factors were compared with 2 categories of serum HER-2 level. Chi-square tests were used for statistical analysis. Kaplan?Meier estimates are presented for the survival and differences in survival were analyzed using log rank test.
Results: The median age was 54 years, median tumor size was 3.2cm. there is no significant correlation between tumor staging and serum HER-2/neu level.(p=0.190). The number of patients with HER-2/neu positive at histopathologic report was correlated with serum HER-2/neu level.(p=0.035) and ER receptor negativity was also correlated with serum HER-2/neu.(p=0.046) The univariate analysis for prognostic factors associated with disease free survival revealed that the serum HER-2/neu as <15ng/ml, °√15ng/ml was statically significant.(p=0.001) and tumor size as T1, T2, T3 or T4 was also statistically significant.(p=0.007) but lymph node status as N0, N1, N2 or N3 was not statistically significant.(p=0.553)
Conclusion: According to our study, serum HER-2/neu was not associated with more advanced staging, ER-status, PR-status, HER-2/neu positive respectively. But there is significant association between serum HER-2/ neu and 3- year disease free survival .
Keywords: serum HER-2/neu | HER-2/neu | breast cancer | DFS
Editorial Office
101-3304 Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
TEL : +82-2-393-2114   FAX : +82-2-393-1649   E-mail : office@kjco.org

Copyright© Korean Society of Surgical Oncology.                Developed in M2PI
About |  Browse Articles |  Current Issue |  For Authors and Reviewers